A Phase 1a Study Evaluating the Safety, Tolerability, and Initial Efficacy of Recombinant Human Anti-cluster Differentiation Antigen 47 (CD47) Monoclonal Antibody Injection (IBI188) in Patients With Advanced Malignant Tumors and Lymphomas
Phase of Trial: Phase I
Latest Information Update: 19 Jul 2019
Price : $35 *
At a glance
- Drugs IBI 188 (Primary)
- Indications Lymphoma; Solid tumours
- Focus Adverse reactions
- Sponsors Innovent Biologics
- 18 Mar 2019 According to the Innovent Biologics media release, first patient has been dosed in this study.
- 08 Feb 2019 Status changed from not yet recruiting to recruiting.
- 12 Dec 2018 New trial record